RxDoctor Payments Data

Thomas Conway, MD

Family Medicine · Newport, TNNPI 1558330241

Payments from drug & device makers

$2,056in general payments, 2019–2025

Across 101 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$448
  • Amarin Pharma, Inc.$293
  • AbbVie$216
  • Bayer$141
  • Novo Nordisk$110
  • Silk Road Medical, Inc.$98
  • plus $750 from 23 others

What the payments were for

  • Food & beverage$2,050100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,056 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$108,375
Medicare patients
155
Services billed
12,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$125,031
EliquisApixaban88$103,178
OzempicSemaglutide70$77,991
LinzessLinaclotide42$44,708
FarxigaDapagliflozin Propanediol43$33,811
XareltoRivaroxaban35$33,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$32,956
EntrestoSacubitril/Valsartan40$22,900
JardianceEmpagliflozin19$22,600
Tresiba Flextouch U-100Insulin Degludec23$18,911
Ondansetron Hcl52$16,776
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen557$16,587
Effexor XrVenlafaxine Hcl12$14,076
Xtampza ErOxycodone Myristate12$11,203
Soliqua 100-33Insulin Glargine/Lixisenatide11$10,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$58$125,03188 claims
PfizerEliquis, Effexor Xr, Paxlovid$64$120,112116 claims
Novo NordiskOzempic$110$77,99170 claims
AbbVieLinzess$216$44,70842 claims
AstraZenecaFarxiga, Symbicort$26$36,24954 claims
Johnson & JohnsonXarelto$54$33,50235 claims
GSKTrelegy Ellipta$448$32,95652 claims
NovartisEntresto$88$22,90040 claims
Collegium Pharmaceutical, Inc.Xtampza Er$46$11,20312 claims
Astellas Pharma US IncMyrbetriq$16$7,07612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Newport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →